Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Integra Lifesciences Holdings's quarterly market cap
declined
from Sep. 2025 (€895 Mil) to Dec. 2025 (€826 Mil) and
declined
from Dec. 2025 (€826 Mil) to Mar. 2026 (€630 Mil).
Integra Lifesciences Holdings's annual market cap
declined
from Dec. 2023 (€3,080 Mil) to Dec. 2024 (€1,636 Mil) and
declined
from Dec. 2024 (€1,636 Mil) to Dec. 2025 (€826 Mil).
Enterprise Value is the theoretical takeover price. It is more comprehensive than market capitalization (market cap), which only includes common equity. Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash and cash equivalents. Integra Lifesciences Holdings's Enterprise Value for Today is €2,841 Mil.
Integra Lifesciences Holdings (STU:IL3) Market Cap Explanation
Market cap is not the real price you pay for a company. If you buy the company and become its owner, you become the owner of the cash the company has, and you also assume the companys debt. The real price you pay is the Enterprise Value.
Warren Buffett uses the ratio of total market cap of all public traded companies over GDP to measure if the market is expensive. As of April 2012, the US total market cap is about $14.7 trillion, while the US GDP is about $15 trillion. The market was modestly overvalued.
Integra Lifesciences Holdings Market Cap Related Terms
Integra Lifesciences Holdings Market Cap Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
STU:IL3 vs ATEC, AHCO, INSP: Market Cap Comparison
For the Medical Devices subindustry, Integra Lifesciences Holdings's Market Cap, along with its competitors' market caps and Market Cap data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Integra Lifesciences Holdings Market Cap vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Integra Lifesciences Holdings's Market Cap distribution charts can be found below:
* The bar in red indicates where Integra Lifesciences Holdings's Market Cap falls into.
Integra Lifesciences Holdings Market Cap Calculation
Market cap is the short version of market capitalization. It is the total market value to buy the whole company. It is equal to the share price times the number of shares outstanding.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Integra Lifesciences Holdings (STU:IL3) has a Market Cap of €1,283 Mil as of Jul. 16, 2026. Market cap equals the total value of a company's shares: price times shares outstanding. View historical data on Integra Lifesciences Holdings and its competitors. According to the industry distribution chart, Integra Lifesciences Holdings ranks #138 out of 866 companies in the Medical Devices & Instruments industry, placing it in the top 15.9%.
Is Integra Lifesciences Holdings' Market Cap too high?
Integra Lifesciences Holdings' current Market Cap is €1,283 Mil. Based on the distribution chart, Integra Lifesciences Holdings ranks #138 out of 866 companies in the Medical Devices & Instruments industry, which is in the top quartile — a strong position relative to peers. Overall, Integra Lifesciences Holdings has a GF Score™ of 74/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Integra Lifesciences Holdings' Market Cap compare to ATEC and AHCO?
According to the Medical Devices & Instruments industry distribution chart, Integra Lifesciences Holdings ranks #138 out of 866 companies for Market Cap. This places Integra Lifesciences Holdings in the top 16% of its industry — outperforming the majority of peers. The industry median Market Cap is 117.90. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Market Cap for a Medical Devices & Instruments company?
The median Market Cap among Medical Devices & Instruments companies is 117.90, based on 866 companies in the industry. Companies in the top quartile (top 25%) have a Market Cap significantly above this median, while those in the bottom quartile fall well below. However, Market Cap should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Market Cap mean?
A high Market Cap can signal that a stock is expensive relative to its fundamentals. Market cap equals the total value of a company's shares: price times shares outstanding. View historical data on Integra Lifesciences Holdings and its competitors. For the Medical Devices & Instruments industry, the median Market Cap is 117.90 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Integra Lifesciences Holdings's current Market Cap is €1,283 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Integra Lifesciences Holdings stock overvalued right now?
Based on GuruFocus' analysis, Integra Lifesciences Holdings (STU:IL3) is currently considered Modestly Undervalued. The stock's GF Value™ is €20.79, compared to a current price of €16.40 — trading 21.1% below its estimated fair value. The current Market Cap is €1,283 Mil. Integra Lifesciences Holdings' overall GF Score™ is 74/100 with 11 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Market Cap calculated?
Market Cap is calculated from a company's financial statements. For Integra Lifesciences Holdings (STU:IL3), the current Market Cap is €1,283 Mil as of Jul. 16, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Integra Lifesciences Holdings (STU:IL3) Overvalued in 2026?
Based on GuruFocus' analysis, Integra Lifesciences Holdings stock appears to be undervalued.
The current stock price of €16.40 is trading 21.1% below its estimated GF Value™ of €20.79.
GuruFocus considers Integra Lifesciences Holdings to be Modestly Undervalued.
Key valuation signals for STU:IL3:
Market Cap: €1,283 Mil
GF Value™: €20.79 vs. price of €16.40 (21.1% below fair value)
No single metric tells the full story. See the STU:IL3 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Integra Lifesciences Holdings Business Description
Integra Lifesciences Holdings Corp is a New Jersey-based medical equipment company focused on developing products for regenerative therapy, extremity orthopedics, and neurosurgical applications. The firm is organized into two primary segments: Codman specialty surgical and Tissue technologies. Codman Specialty Surgical generates maximum revenue from its segmental operations. Integra serves Europe, Asia Pacific, and the rest of the world whilst it derives key revenue from domestic sales. The company operates in United States, Europe, Asia Pacific, and Rest of the World.
74GF Score
Get the complete analysis for STU:IL3
Market Cap is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
STU:IL3 has been successfully added to your 
